Invesco Ltd. Sells 156,130 Shares of Xencor, Inc. (NASDAQ:XNCR)

Invesco Ltd. reduced its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 25.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 454,745 shares of the biopharmaceutical company's stock after selling 156,130 shares during the period. Invesco Ltd. owned about 0.65% of Xencor worth $10,450,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of XNCR. Barclays PLC grew its position in Xencor by 100.7% during the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock valued at $3,128,000 after buying an additional 78,066 shares during the period. Geode Capital Management LLC boosted its position in shares of Xencor by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company's stock valued at $29,273,000 after acquiring an additional 17,658 shares during the period. Sanctuary Advisors LLC purchased a new position in shares of Xencor during the 3rd quarter valued at $540,000. JPMorgan Chase & Co. grew its position in Xencor by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 130,354 shares of the biopharmaceutical company's stock worth $2,621,000 after buying an additional 3,635 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 508 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. William Blair started coverage on shares of Xencor in a research note on Monday. They issued an "outperform" rating for the company. StockNews.com downgraded Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Finally, Wells Fargo & Company lowered their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $33.86.

Xencor Trading Up 0.5 %

XNCR stock opened at $10.65 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a fifty-two week low of $7.16 and a fifty-two week high of $27.24. The firm has a fifty day moving average price of $12.10 and a 200 day moving average price of $18.60. The firm has a market cap of $750.42 million, a PE ratio of -3.33 and a beta of 0.90.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Sell-side analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.